Literature DB >> 20717480

Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.

Odelia Cooper1, Anat Ben-Shlomo, Vivien Bonert, Serguei Bannykh, James Mirocha, Shlomo Melmed.   

Abstract

Silent corticotrophins adenomas (SCAs) are clinically silent and non-secreting but immunostain positively for ACTH. We hypothesize that SCAs comprise both corticotroph and gonadotroph characteristics. Cohort analysis from 1994-2008 with follow-up time ranging from 1-15 years in a tertiary referral center. We compared preoperative and postoperative clinical results and tumor cytogenesis in 25 SCAs and 84 nonfunctioning adenomas in 109 consecutive patients diagnosed pre-operatively with nonfunctioning pituitary adenomas. Clinical outcomes were radiologic and hormonal measures. Pathologic outcomes were expression of relevant pituitary hormones, tissue-specific transcription factors, and electron microscopy features. Preoperative SCA presentation was similar to that observed for nonfunctioning adenomas. However, SCAs recurred postoperatively at a median of 3 years vs. 8 years for nonfunctioning adenomas (p<0.0001). Fifty-four percent of patients with SCAs had new onset postoperative hypopituitarism vs. 17% of nonfunctioning adenomas (p<0.025). SCAs (n=18) were immunopositive for ACTH, cytoplasmic and nuclear SF-1, NeuroD1, DAX-1, and alpha-gonadotropin subunit, but Tpit negative, and co-expression of tumor ACTH with either SF-1 or LH was detected. In contrast, functional corticotroph adenomas (n=11) were immunopositive for ACTH, nuclear SF-1, NeuroD1, and Tpit, but negative for DAX-1, a gonadotroph cell transcription factor. Gonadotroph adenomas (n=23) were immunonegative for ACTH and Tpit but positive for nuclear SF-1, NeuroD1, and DAX-1. SCA electron microscopy demonstrated ultrastructural features consistent with corticotroph and gonadotroph cells. As SCAs exhibit features consistent with both corticotroph and gonadotroph cytologic origin, we propose a pathologic and clinically distinct classification of SCAs as silent corticogonadotroph adenomas.

Entities:  

Keywords:  Corticotroph adenoma; Gonadotroph adenoma; Nonfunctioning adenoma; Pituitary adenoma

Mesh:

Substances:

Year:  2010        PMID: 20717480      PMCID: PMC2921667          DOI: 10.1007/s12672-010-0014-x

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  57 in total

1.  NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene.

Authors:  G Poulin; B Turgeon; J Drouin
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

2.  A rapid method for reprocessing paraffin sections for diagnostic electron microscopy.

Authors:  H K Ngai; K W Chan; S B Or; W L Yau
Journal:  J Pathol       Date:  1985-01       Impact factor: 7.996

3.  Dax-1 as one of the target genes of Ad4BP/SF-1.

Authors:  K Kawabe; T Shikayama; H Tsuboi; S Oka; K Oba; T Yanase; H Nawata; K Morohashi
Journal:  Mol Endocrinol       Date:  1999-08

4.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

5.  Developmental dependence on NurRE and EboxNeuro for expression of pituitary proopiomelanocortin.

Authors:  Pierre-Luc Lavoie; Lionel Budry; Aurélio Balsalobre; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2008-04-03

Review 6.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  "Honeycomb Golgi" in pituitary adenomas: not a marker of gonadotroph adenomas.

Authors:  Toshiaki Sano; Rene Mader; Sylvia L Asa; Zhi Rong Qian; Akiko Hino; Shozo Yamada
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

8.  A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.

Authors:  Shozo Yamada; Kenichi Ohyama; Manabu Taguchi; Akira Takeshita; Koji Morita; Koji Takano; Toshiaki Sano
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

9.  Expression of an orphan nuclear receptor DAX-1 in human pituitary adenomas.

Authors:  S Ikuyama; Y M Mu; K Ohe; H Nakagaki; T Fukushima; R Takayanagi; H Nawata
Journal:  Clin Endocrinol (Oxf)       Date:  1998-05       Impact factor: 3.478

10.  Differential gene expression in ACTH -secreting and non-functioning pituitary tumors.

Authors:  Toru Tateno; Hajime Izumiyama; Masaru Doi; Takanobu Yoshimoto; Masayoshi Shichiri; Naoko Inoshita; Kenichi Oyama; Shozo Yamada; Yukio Hirata
Journal:  Eur J Endocrinol       Date:  2007-12       Impact factor: 6.664

View more
  26 in total

Review 1.  Functional Gonadotroph Adenomas: Case Series and Report of Literature.

Authors:  David J Cote; Timothy R Smith; Courtney N Sandler; Tina Gupta; Tejus A Bale; Wenya Linda Bi; Ian F Dunn; Umberto De Girolami; Whitney W Woodmansee; Ursula B Kaiser; Edward R Laws
Journal:  Neurosurgery       Date:  2016-12       Impact factor: 4.654

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 3.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

4.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.

Authors:  Hiroshi Nishioka; Naoko Inoshita; Ozgur Mete; Sylvia L Asa; Kyohei Hayashi; Akira Takeshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Yasuhiro Takeuchi; Shozo Yamada
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

5.  Expression of the pituitary stem/progenitor marker GFRα2 in human pituitary adenomas and normal pituitary.

Authors:  Nestoras Mathioudakis; Ram Sundaresh; Alexandra Larsen; William Ruff; Jennifer Schiller; Hugo Guerrero-Cázares; Peter Burger; Roberto Salvatori; Alfredo Quiñones-Hinojosa
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

6.  Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study.

Authors:  Or Cohen-Inbar; Zhiyuan Xu; Cheng-Chia Lee; Chin-Chun Wu; Tomáš Chytka; Danilo Silva; Mayur Sharma; Hesham Radwan; Inga S Grills; Brandon Nguyen; Zaid Siddiqui; David Mathieu; Christian Iorio-Morin; Amparo Wolf; Christopher P Cifarelli; Daniel T Cifarelli; L Dade Lunsford; Douglas Kondziolka; Jason P Sheehan
Journal:  J Neurooncol       Date:  2017-09-14       Impact factor: 4.130

Review 7.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

8.  Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification.

Authors:  Marie Buchy; Véronique Lapras; Muriel Rabilloud; Alexandre Vasiljevic; Françoise Borson-Chazot; Emmanuel Jouanneau; Gérald Raverot
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 9.  Silent corticotroph adenomas.

Authors:  Odelia Cooper
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

10.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.